2026 Q2 -tulosraportti
Äänite tulossa
2 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·13 t sittenSEB lowers the target price. To 299 😝😆🎂🍷
Good that they confirm that they see a high target price, but that they set 290 instead of 330 is pure nonsense. They don't have a basis for making that assessment - just as little as we do. Probably just want it to look like they've thought.
·2 päivää sittenToday's newsletter / Quarterly data ... The delay of a few months is not considered critical for the approval chance, as it is primarily due to PPQ/CMC and not new clinical problems. It is of course annoying, but it does not affect future earnings, merely a timing issue and disappointment here and now. FDA has already reviewed Phase II and III data and has not currently required a new clinical study. The most important short-term milestone is therefore the completion of PPQ production and the final documentation. BLA is realistically estimated for December 2026 – January/February 2027, which is still a relatively limited time shift. The regulatory picture is simultaneously strengthened by EMA's assessment that IBT has fulfilled its PIP obligations. The commercial potential is significant, with a realistic US peak sales of around USD 400–500 mio. annually. A strong FDA label can further lift the potential and simultaneously make IBP-9414 attractive to larger commercial partners. Overall, the case is still considered strong: the delay primarily affects timing, while FDA approval, label, and commercialization are the decisive value drivers. *disclamer. I have a cardboard box full of Infant shares. Make your own assessment.
Yes, unfortunately a "minor operational error" occurred, as stated in the report. Then it's certainly better that it gets rectified. They also emphasize how important IBP-9414 is and in the same Class as when the Surfactants came 25 years ago.
·21.8.Who is with us for the earnings report here? Since before the summer holiday and the announcement of a new CFO (from October), this has exclusively gone sideways. Does anyone have new information? I know that it has been announced that the applications for IBP-9414 should be submitted in the second half of 2026. Let's hope that there is new information in connection with the earnings report on Wednesday. I'm crossing my fingers that we can pass price 72 in connection with the earnings report, because then the path to over 100 should be secured! After this, we will probably have to wait until the first half of 2027 before larger movements occurPS: I have this time been involved since 20 spril. I have previously been in this stock on 2 occasions. first time around the turn of the year 2022 (bad investment) and second time in 2nd half 2023 (ok investment). so will hold it until ultimo 2026 and fsælge before year-end and thereafter buy up a couple of months before an approval possibly is achieved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
Äänite tulossa
2 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenSEB lowers the target price. To 299 😝😆🎂🍷Good that they confirm that they see a high target price, but that they set 290 instead of 330 is pure nonsense. They don't have a basis for making that assessment - just as little as we do. Probably just want it to look like they've thought.
- ·2 päivää sittenToday's newsletter / Quarterly data ... The delay of a few months is not considered critical for the approval chance, as it is primarily due to PPQ/CMC and not new clinical problems. It is of course annoying, but it does not affect future earnings, merely a timing issue and disappointment here and now. FDA has already reviewed Phase II and III data and has not currently required a new clinical study. The most important short-term milestone is therefore the completion of PPQ production and the final documentation. BLA is realistically estimated for December 2026 – January/February 2027, which is still a relatively limited time shift. The regulatory picture is simultaneously strengthened by EMA's assessment that IBT has fulfilled its PIP obligations. The commercial potential is significant, with a realistic US peak sales of around USD 400–500 mio. annually. A strong FDA label can further lift the potential and simultaneously make IBP-9414 attractive to larger commercial partners. Overall, the case is still considered strong: the delay primarily affects timing, while FDA approval, label, and commercialization are the decisive value drivers. *disclamer. I have a cardboard box full of Infant shares. Make your own assessment.Yes, unfortunately a "minor operational error" occurred, as stated in the report. Then it's certainly better that it gets rectified. They also emphasize how important IBP-9414 is and in the same Class as when the Surfactants came 25 years ago.
- ·21.8.Who is with us for the earnings report here? Since before the summer holiday and the announcement of a new CFO (from October), this has exclusively gone sideways. Does anyone have new information? I know that it has been announced that the applications for IBP-9414 should be submitted in the second half of 2026. Let's hope that there is new information in connection with the earnings report on Wednesday. I'm crossing my fingers that we can pass price 72 in connection with the earnings report, because then the path to over 100 should be secured! After this, we will probably have to wait until the first half of 2027 before larger movements occurPS: I have this time been involved since 20 spril. I have previously been in this stock on 2 occasions. first time around the turn of the year 2022 (bad investment) and second time in 2nd half 2023 (ok investment). so will hold it until ultimo 2026 and fsælge before year-end and thereafter buy up a couple of months before an approval possibly is achieved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
2026 Q2 -tulosraportti
Äänite tulossa
2 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 13.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 26.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
2025 Q4 -tulosraportti 6.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 20.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·13 t sittenSEB lowers the target price. To 299 😝😆🎂🍷Good that they confirm that they see a high target price, but that they set 290 instead of 330 is pure nonsense. They don't have a basis for making that assessment - just as little as we do. Probably just want it to look like they've thought.
- ·2 päivää sittenToday's newsletter / Quarterly data ... The delay of a few months is not considered critical for the approval chance, as it is primarily due to PPQ/CMC and not new clinical problems. It is of course annoying, but it does not affect future earnings, merely a timing issue and disappointment here and now. FDA has already reviewed Phase II and III data and has not currently required a new clinical study. The most important short-term milestone is therefore the completion of PPQ production and the final documentation. BLA is realistically estimated for December 2026 – January/February 2027, which is still a relatively limited time shift. The regulatory picture is simultaneously strengthened by EMA's assessment that IBT has fulfilled its PIP obligations. The commercial potential is significant, with a realistic US peak sales of around USD 400–500 mio. annually. A strong FDA label can further lift the potential and simultaneously make IBP-9414 attractive to larger commercial partners. Overall, the case is still considered strong: the delay primarily affects timing, while FDA approval, label, and commercialization are the decisive value drivers. *disclamer. I have a cardboard box full of Infant shares. Make your own assessment.Yes, unfortunately a "minor operational error" occurred, as stated in the report. Then it's certainly better that it gets rectified. They also emphasize how important IBP-9414 is and in the same Class as when the Surfactants came 25 years ago.
- ·21.8.Who is with us for the earnings report here? Since before the summer holiday and the announcement of a new CFO (from October), this has exclusively gone sideways. Does anyone have new information? I know that it has been announced that the applications for IBP-9414 should be submitted in the second half of 2026. Let's hope that there is new information in connection with the earnings report on Wednesday. I'm crossing my fingers that we can pass price 72 in connection with the earnings report, because then the path to over 100 should be secured! After this, we will probably have to wait until the first half of 2027 before larger movements occurPS: I have this time been involved since 20 spril. I have previously been in this stock on 2 occasions. first time around the turn of the year 2022 (bad investment) and second time in 2nd half 2023 (ok investment). so will hold it until ultimo 2026 and fsælge before year-end and thereafter buy up a couple of months before an approval possibly is achieved
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt